Akston’s AKS-699 Demonstrates One-Year Pruritus Control with Fewer Treatments
BEVERLY, Mass., June 16, 2026 Akston Biosciences Corporation has announced promising preclinical data demonstrating that its investigational immunotherapeutic AKS-699...
Implantable Devices
Advertisement
SonoClear Study Selected for EANS 2026 Oral Presentation
OSLO, Norway, June 16, 2026 SonoClear AS has announced that findings from its pivotal multicenter study evaluating the SonoClear®...
Nervonik Completes First Human Nerve Sensing Study
LOS ANGELES, June 16, 2026 Nervonik Inc., a clinical-stage medical device company focused on next-generation neuromodulation technologies, has announced...
Nyxoah Expands Genio Sleep Apnea Therapy Access
Middle East Partnership Advances Neurostimulation Care – February 18, 2026 | Mont-Saint-Guibert, Belgium Nyxoah has signed a Memorandum of...
Artificial Heart Bridge Enables Successful Transplant
TUCSON, Ariz., Feb. 12, 2026 — Picard Medical, parent company of SynCardia Systems, announced a landmark bridge-to-transplant milestone at...
Advertisement
